A similar assessment was performed by Shin K.H. et al. [56] evaluating the clinical utility of CA125, HE4 and CA72-4, and ROMA in the differential diagnosis of malignant and borderline tumours among women (N = 266; 213 benign tumours, 14 borderline tumours and 39 malignant tumours). The gene discussed is MUC16; the disease is cancer.